Literature DB >> 21674571

Practical aspects of the oral new anticoagulants.

Thomas G DeLoughery1.   

Abstract

After years of only oral vitamin K antagonists, there are new many new antithrombotic agents in development and on entering the marketplace. This review will analyze clinical trial results for these new agents-especially dibigatran, rivaroxaban, and apixiban. Also to be discussed are practical aspects of use of these new agents such monitoring, reversal, and use before procedures.
Copyright © 2011 Wiley-Liss, Inc.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21674571     DOI： 10.1002/ajh.22021

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  4 in total

1.  Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin.

Authors:  Sebastian Härtter; Michael Koenen-Bergmann; Ashish Sharma; Gerhard Nehmiz; Ute Lemke; Wolfgang Timmer; Paul A Reilly
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

Review 2.  Interrupted versus uninterrupted anticoagulation therapy for catheter ablation in adults with arrhythmias.

Authors:  Ghada A Bawazeer; Hadeel A Alkofide; Aya A Alsharafi; Nada O Babakr; Arwa M Altorkistani; Tarek S Kashour; Michael Miligkos; Khalid M AlFaleh; Lubna A Al-Ansary
Journal:  Cochrane Database Syst Rev       Date:  2021-10-21

3.  Recent advances in the diagnosis and treatment of heparin-induced thrombocytopenia.

Authors:  Tamam Bakchoul; Andreas Greinacher
Journal:  Ther Adv Hematol       Date:  2012-08

4.  How minimally interrupted direct oral anticoagulants affect intraprocedural anticoagulation during atrial fibrillation ablation? Insights from a Japanese single-center retrospective study.

Authors:  Masahiro Mizobuchi; Atsushi Funatsu; Tomoko Kobayashi; Shigeru Nakamura
Journal:  J Arrhythm       Date:  2019-08-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.